This document discusses research and development (R&D) and innovation management at Mankind Pharma. It provides background on Mankind Pharma, founded in 1995, which now has over 10,000 employees and operates in 15 countries. It outlines the objectives of R&D including quality improvement and new product development. It also describes Mankind Research Centre, located in Gurgaon, which has over 200 scientists working on over 200 projects, including new drug discovery. The document emphasizes Mankind Pharma's commitment to R&D, investing over $100 million annually.

1. GOOD MORNING

2. What is R&D???
R&D MAKES A SIGNIFICANT CONTRIBUTION TO
THE COMPETITIVE STRENGTH OF INDUSTRIES,
LARGE AS WELL AS SMALL,IN NATIONAL AS WELL
AS INTERNATIONAL MARKETS “INNOVATE OR
PERISH” IS THE LAW OF THE LAND. NOW-A-DAYS
BEING GREATEST IS NOT IMPORTANT, BUT ALL
THE MORE IMPORTANT IS THAT OF BEING LATEST.

3. OBJECTIVES OF R&D
• QUALITY IMPROVEMENT
• COST REDUCTION
• OVERCOMING PROCESS PROBLEMS
• CONSUMER DELIGHT OR MARKET NEEDS
• EXPLOITING THE OPPORTUNITY IN THE
MARKET FOR A NEW PRODUCT
• EXPANSION & DIVERSIFICATION

4. • PRODUCT INNOVATION
• PROCESS INNOVATION
• PRODUCT DEVELOPMENT

5. MANAGEMENT OF TECHNOLOGY
THE VARIOUS KEY STRATEGIC ISSUES ARE:
1.SOURCE OF NEW TECHNOLOGY
2.CHOICE OF NEW TECHNOLOGY
3.TRANSFER & DIFFUSION OF TECHNOLOGY
4.APPLICATION OF TECHNOLOGY
5.TIMING OF INTRODUCTION

6. TECHNOLOGY LIFE CYCLE
• ALL OBJECTS & SYSTEMS HAVE LIFE CYCLES
IN THE FORM OF EMERGECE, GROWING,
MATURING & DECLINING.THIS IS TRUE FOR A
TECHNOLOGY TOO.

7. TECHNOLOGICAL FORECASTING
• IT USES THE PAST AND PRESENT KNOWLEDGE
TO BUILD THE FUTURE
• IT PUTS EMPHASIS ON A SPECIFIC
DEVELOPMENT
• IT PROMISES TO SERVE USEFUL FUNCTION
• IT PROVIDES USEFUL DATA
• IT HELPS TO REDEFINE ITS BUSINESS PROPERLY
• IT ENABLES AN ORGANISATION TO AVOID
COSTLY MISTAKES & WASTAGES

8. BARRIERS IN TECHNOLOGY
MANAGEMENT
• LACK OF KNOWLEDGE &TRAINING
• LACK OF LONG RANGE FOCUS
• LACK OF RISK TAKING

9. INNOVATION MANAGEMENT
INNOVATION IS THE PROCESS OF
INTRODUCING NEW WAYS OF DOING THINGS.
“THE ACT OF INTRODUCING SOMETHING
NEW OR SOMETHING NEWLY INTRODUCED.”
----THE AMERICAN HERITAGEDICTIONARY
“ANY PRODUCT , SERVICE OR IDEA THAT IS
PERCEIVED AS NEW.”
----ROGERS

10. INNOVATION IN THE NATURE OF
NEWNESS
• RADICAL INNOVATION
• SYSTEM INNOVATION
• INCREMENTAL INNOVATION

11. MANAGEMEENT OF INNOVATION
1.GENERATION OF INNOVATION
A.IDENTIFYING NEED FOR INNOVATION
B.IDEA GENERATION
C.IDEA EVALUATION
D.IDEA SELECTION

12. 2.INNOVATION DIFFUSION
• AWARENESS ABOUT THE INNOVATION OCCURING
OUTSIDE THE ORGANISATION
• ASSESSING THE RELEVANCE OF INNOVATION TO
THE ORGANISATION
• TRYING THE INNOVATION TO JUDGE ITS
FEASIBILITY
• ADOPTION OF THE FEASIBLE INNOVATION

13. AN EFFICIENT MANAGEMENT OF INNOVATION
REQUIRES FOLLOWING TWO ITEMS.
1.LEARNING ORGANISATION
2.KNOLEDGE MANAGEMENT

14. LEARNING ORGANISATION
THE ORGANISATION WHICH
ANTICIPATES LIKELY CHANGES IN THE
ENVIRONMENT & GEAR THEIR HUMAN
RESOURCES TO FACE THE ENVIRONMENTAL
THREATS THAT ARE LIKELY TO BE POSED.SUCH
ORGANISATION EMPHASIZES CONTINUOUS
ORGANISATIONAL LEARNING AND ARE KNOWN
AS LEARNING ORGANISATION.

15. DEFINITION
GARWIN :
“A LEARNING ORGANISATION IS ONE
WHICH IS SKILLED AT CREATING, ACQURING,
AND TRANSFERRING KNOWLEDGE &
MODIFYING ITS BEHAVIOUR TO REFLECT NEW
KNOOWLEDGE & INSIGHTS.”

16. CHARACTERISTICS
• SHARED VISION
• FORMULATION & IMPLEMENTATION OF IDEAS
• COLLABORATION LEARNING
• EMPOWERMENT & LEADERSHIP
• LEARNING CONTINUOUSLY

17. TYPES
• ADAPTIVE LEARNING
• GENERATIVE LEARNING

18. DEVELOPING A LEARNING
ORGANISATION
• TOP MANAGEMENT COMMITMENT
• SHARED VISION
• ACCEPTABILITY OF LEARNING
• INTRODUCING NEW STRUCTURES,
TECHNIQUES & PROCESS ETC.
• REINFORCEMENT/COMMITMENT OF ENTIRE
WORKERS
• LEARNING CULTURE

19. KNOWLEDGE MANAGEMENT
IT IS CREATION, DISTRIBUTION &
UTILISATION OF KNOWLEDGE AT THE
INDIVIDUAL, GROUP, ORGANISATIONAL &
COMMUNIITY LEVELS THROUGH HARNESSING
OF PEOPLE,PROCESS& TECHNOLOGY FOR THE
BENEFITS OF THOSE INVOLVED & AFFECTED
BY IT.

20. BASIC ELEMENTS
• KNOWLEDGE CREATION
• KNOWLEDGE SHARING
• KNOWLEDGE UTILISATION

22. SUN PHARMACEUTIAL INDUSTRIES
LTD.
• Sun Pharmaceutial industries ltd.(NSE:SUNPHARMA,BSE:524715)is a
multinational Pharmaceutial company.
• Its headquarter in Mumbai
• It was established by Dilip Shanghvi in 1983
• It was listed in stock exchange in1994
• It manufactures and sells pharmaceutial formulations and Active
Pharmaceutical Ingredients(API) primarily in India and United states
• The company offers formulations in various therapeutic areas, such as
cardiology,psychiatry,neurology,gastroenterology and diabetology.
• It also provides APIs such as warfarin, carbamazepine, etodolac, and
clorazepate, as well as anticancers steroids, peptides and controlled
substances.

23. MAJOR ACQUSITIONS
• 2014-Ranbaxy laboratories ltd.
• 2013-URL Pharma
• 2012-Dusa pharmaceuticals
• 2011-MSD
• 2010-Carco,Taro
• 2009-Inwood Laboratories,Inc
• 2008-Chattem Chemicals,Inc
• 2005-ABLE LABORATORIES

24. AWARDS
• Mr. Dilip Shanghvi receives Entrepreneur of the Year by Forbes Magazine
• Sun Pharma receives Cardiovascular Pharmaceutical Company of the Year
by Forest&Sullivan India Health Care Excellence Awards
• Mr. Dilip Shanghvi receives Business Leader of The Year Award
by The Economics Times
• Sun Pharma is listed among The world’s 100 most innovative Companies
by Forbes
• Mr. Dilip Shanghvi receives JRD TATA Corporate Leadership Award
by All India Management Association

25. R AND D CENRES
New York, USA (Taro) Vadodara, India

26. Mumbai, India Haifa, Israel (Taro)

27. Brampton, Canada (Taro) Gurgaon, India

28. DUSA, USA Cranbury, USA

29. R & D EXPENDITURE
Year 2004-
05
2005-
06
2006-
07
2007-
08
2008-
09
2009-
10
2010-
11
2011-
12
2012-
13
2013-
14
Total 1427 2015 2787 2859 3320 2242 3313 4449 7042 10418
Revenue 418 481 347 134 222 159 236 362 427 556
Capital 1009 1534 2440 2725 3098 2083 3077 4087 6615 9862
% to
revenue
12% 12% 13% 9% 8% 6% 6% 6% 6% 7%

32. MAN BEHIND THE COMMITMENT

33. HISTORY AT A GLANCE
FOUNDED BY R.C. JUNEJA IN1995 AT A SEED CAPITAL
OF 50 LAKHS WITH ONLY 20 EMPLOYEES.
PRODUCTS IN THERAPEUTIC AREA RANGING
FROM ANTIBIOTIC & ANTIFUNGALCOMPOUNDS
TO GASTROINTESTINAL,CARDIOVASCULAR,DERMAL
&ERECTILE DYSFUNCTIONAL MEDICATIONS.
HEAD QUARTER-OKHLA ,NEWDELHI.
REVENUE-3000 CRORES cont…

34. SUBSIDIARIES- DISCOVERY, LIFESTAR, SPECIAL,
VET, FUTURE,MAGNET.
NO. OF EMPLOYEES-10000+
POPULAR PRODUCTS-MOXIKIND-CV, GUDCEF ,
ALMOKIND-AT ,NUROKIND/PLUS ,
MANFORCE,PREGANEWS,GAS-O-FAST,
ADDICTION DEODRANT
NO. OF COUNTRY OPERATE-15

35. AWARDS AND RECOGNITIONS
• “EMERGING COMPANY OF THE YEAR” AT
PHARMA EXCELLENCY AWARD,2007
• “ENTREPRENEUR OF THE YEAR” BY ERNST AND
YOUNG,2011
• “INDIA BUSINESS ICON(PHARMA)AWARD”
BYNETWORK 18,2011
• “ACHIEVING BUSINESS EXCELLENCE AWARD” BY
CITI COMMERCIAL BANK,2012

36. MISSION
“TO IMPROVE THE QUALITY OF LIFE TO
CONTINUE TO BE RECOGNISED AS A RELIABLE
PROVIDER OF HEALTHCARE PRODUCTS AND
NURTURE INNOVATION THAT LEADS TO COLLECTIVE
EXCELLENCE..”
VISION
“TO ENSURE REACH,AFFORDABILITY AND
QUALITY OF OUR PRODUCTS,ACROSS THE
COUNTRY FOR A HEALTHIER AND HAPPIER INDIA.”

37. MANKIND RESEARCH CENTRE
• LOCATED IN MANESAR (GURGAON, HARYANA)
• ADMINISTERED BY MORE THAN 200 LEADING SCIENTISTS
FROM DIVERSE FIELDS
• 200+ PROJECTS IN PIPELINE
• 5 NEW DRUG DISCOVERY PROJECTS
• RICH HUMAN CAPITAL AND HIGH TECH EQUIPMENT MAKES
MANKIND A PIONEER IN THE FIELD OF R&D.
ITS DEVELOPMENT CAPABILITIES INCLUDES:

38. 1.NEW DRUG DISCOVERY AND
RESEARCH
• IT FOCUSES ON THE DISCOVERY
OF,DEVELOPMENT,RESEARCH AAND
COMMERCIALIZATION OF NEW DRUGS THAT
ADDRESS DISEASE AREAS WITH SIGNIFICANTLY
UNMET MEDICAL NEED.
• EFFORTS DIRECCTED TOWARDS IDENTIFYING AND
DEVELOPING NEW THERAPIES FOR DISEASE AREA
INCLUDE DIABETES, ARTHRITIS & ANGINA.

39. 2.ACTIVE PHARMACEUTICAL
INGREDIENTS
• ADVANTAGE TO CONDUCT COMPLEX
REACTIONS WITH PROPER INFRASTRUCTURE
• PRESENTLY IT IS DEVELOPING APIS LIKE
ANTIBIOTICS,,ANTIPSHYCHOTIC,ANTIBACTERI
AL,ANTIINFLAMMATORY,ANTIASTHMATIC,ANT
IALLERGIC,ANTI DIABETES,AND CALCIUM
CHANNEL BLOCKERS,DRUGS FOR
ARTHRITIS,OSTEOARTHRITIS AND STEROIDS.

40. 3.FORMULATION RESEARCH
AND DEVELOPMENT
• OCCUR ACROSS MAJOR THERAPEUTIC AREAS LIKE-
GASTRO INTESTINAL AILMENTS, CARDIOVASCULAR
DISEASE,PAIN MGMT., ONCOLOGY,PAEDIATRIC-TO
DELIVER INTELLECTUAL PROPERTY TO THE
ORGANIZATION.
• CURRENTLY IT IS WORKING ON ENHANCING THE
BIOAVAILABILITY OF MOLECULES WHICH MAY LEAD
TO REDUCTIO IN DOSE & INCREASE THE SAFETY
PROFILE OF DRUG.

41. 4.ANALYTICAL R&D
• ANALYTICAL R&D INVOLVES PRE-
FORMULATION,STABILITY& DEGRADATION
STUDIES ON APIS & OTHER DRUGS,&
PREPARATION OF TECHNICAL DOSSIERS FOR
REGISTRATION IN INDIA & OTHER COUNTRIES.
• THE ANALYTICAL DEVELOPMENT TEAM
PROVIDES SPECIFIC SERVICE TO VARIOUS
DEPTTS OF MANKIND RESEARCH CENTRE.

42. 5.INTELLECTUAL PROPERTY MGMT.
• IT HAS AN EXPERIENCED TEAM OF IP
PROFESSIONALS SPECIALIZEDIN IP LAWS THAT
WORKS DILIGENTLY TO ENSURE THE
PROTECTION OF MANKIND’S IP WEALTH.

43. PRODUCTS(DOMESTIC FORMULATIONS)
1.MANKIND PHARMA:
• JOURNEY BEGINS IN 1995
• PRODUCT AREA-
CARDIOVASCULAR,ANTIBIOTICS,GASTRO
INTESTINAL,ANTI-ALLERGIC,ANTI-
FUNGAL,NUTRITIONAL ETC.
• SUCCESSFUL PRODUCTS-
NORAGYL,RANISPAS,RANIDOMIN,NUROKIND,MOXIKI
ND,TELMIKIND ETC.

44. 2.DISCOVERY MANKIND
• ESTABLISH IN 2002.
• PRODUCT AREA-ANTI-DIABETIC,ANTI-
INFECTIVE,GYNAECONOLOGICAL,NUTRITIONALS
,ANTI-ALLERGIC ETC.
• FIRST RANKSED BRANDS-
MAHAAAAAFLOX,LIZOFORCE,CANDIFORCE,FYNAL-
OZ,MONTICOPE ETC.

45. 3.FUTURE MANKIND
• ESTABLISHED IN 2007
• PRODUCT BASE-SPECIALISE IN
MANUFACTURING OF PRODUCTS FOR
NEUROPSHYCHIATRY & DENISTRY
• TOP PRODUCTS-
CLONAFIT,RANIDOM,FLORA,THERMOKIND,
HISTAFREE ETC.

46. 4.SPECIAL MANKIND
• HEAL-O-KIND,
• KALOREE 1
• GAS-O-FAST
• ADDICTION
• MANFORCE TABLET
• STAY LONG GEL AND ETC.

47. 5.VET MANKIND
• FENDIKIND PLUS BOLUS
• MEGABLOTA SUSPENSION
• BANDYKIND PLUS BOLUS
• NUROKIND-PLUS VET INJECTION
• ENERDYNA LIQUID ETC.

48. LIFESTAR
• ESTABLISHED IN2005
• PRODUCT BASE-
OPTHALMOLOGY,ANTIBIOTICS,ANTI-
MALARIA,DERMATOLOGY ETC.
• PRODUCTS BRAND-
TERBINAFORCE,OSKAR,ASTHAKIND,VENTIDOX-
DL ETC.

49. MAGNET
• START OPERATION-2007
• PRODUCT BASE- COVERS ALL THERAPEUTIC AREA
LIKE NUTRITIONAL,ANTI-BACTERIAL,GASTRO-
INTESTENIAL,,PAIN MGMT.,CENTRAL NERVOUS
SYSTEM ETC.
• PRODUCT BRANDS-BRUTACEF,NUROKIND
FORTE,RACIGYL-SB,RANIDOM-RD,UBINEXT-
LC,GUT-OK ETC,

50. INTERNATIONAL MARKET OPERATION
• NO. OF PRODUCTS-300+
• NO.OF COUNTRIES-15
• REGULATORY AFFAIRS MECHANISM

51. THANK YOU